IDEAYA Biosciences (NASDAQ:IDYA) Price Target Increased to $68.00 by Analysts at Stifel Nicolaus
IDEAYA Biosciences (NASDAQ:IDYA – Free Report) had its price target boosted by Stifel Nicolaus from $63.00 to $68.00 in a research report report published on Tuesday morning, Benzinga reports. They currently have a buy rating on the stock. Several other research analysts have also commented on IDYA. Mizuho initiated coverage on shares of IDEAYA Biosciences […]
More Stories
International Game Technology PLC (NYSE:IGT) Receives Average Rating of “Moderate Buy” from Analysts
Shares of International Game Technology PLC (NYSE:IGT – Get Free Report) have earned a consensus rating of “Moderate Buy” from...
EZFill Holdings, Inc. Faces Potential Delisting from Nasdaq for Failure to Hold Annual Meeting
On January 10, 2025, EZFill Holdings, Inc. (NASDAQ:EZFL) received a notice from The Nasdaq Stock Market LLC (Nasdaq) stating that...
Integra LifeSciences (NASDAQ:IART) and Steakholder Foods (OTCMKTS:MTTCF) Head to Head Analysis
Integra LifeSciences (NASDAQ:IART – Get Free Report) and Steakholder Foods (OTCMKTS:MTTCF – Get Free Report) are both medical companies, but...
QCR Holdings, Inc. (NASDAQ: QCRH) Enters Consulting Services Agreement with John H. Anderson
QCR Holdings, Inc., a financial holding company headquartered in Moline, Illinois, disclosed a notable development in a recent 8-K filing...
Moleculin Biotech (NASDAQ:MBRX) Corporate Presentation Available OnlineOn January 8, 2025, Moleculin Biotech, Inc. (the “Company”) made public its corporate presentation, which is now accessible on the Company’s official website. The presentation det
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For...
**Formula One Group Appoints Derek Chang as President and CEO**
Formula One Group, a subsidiary of Liberty Media Corporation (NASDAQ: FWONK), announced significant executive changes in a recent 8-K filing...